Tilray, Inc. is a Canada-based CBD company that describes itself on its website as a “global leader in cannabis research, cultivation, processing, and distribution.” The company aspires “to lead, legitimize and define the future of our industry by building the world’s most trusted cannabis company.”
The company recently announced in a press release that it is importing Good Manufacturing Practices Certified CBD into the United States for two clinical trials. The clinical trials will be conducted by the NYU School of Medicin and will specifically test the CBD for treatment of patients with alcohol use disorders, post-traumatic stress disorders, and alcohol use disorders.
The first of the clinical trials will be double-blind and randomized, designed to assess CBD treatment for those who have AUD. Those leading the trial will evaluate factors such as safety and tolerability of using CBD on a regular basis among the treatment population. It will also look into whether CBD has an impact on neuropsychological and neurophysiological domains related to AUD.
A second clinical trial will be double-blind and randomized as well and is designed to assess CBD treatment among patients with PTSD and alcohol use related to PTSD. It will also assess the tolerability, efficacy, and safety of using CBD among the population.
Phillippe Lucas, the VP of Global Patient Research and Access at Tilray, shared in the press release
“We’re proud to support these two clinical trials led by NYU School of Medicine.” He added, “Tilray is committed to supporting research that can provide further evidence for the safety and efficacy of medical cannabis and, ultimately, data to support the treatment of more patients in need around the world.”
Dr. Marmar of the NYU School of Medicine also shared in the press release,
“NYU School of Medicine enjoys an outstanding reputation in advancing the study of CBD for its use in treating several illnesses, most notably various forms of epilepsy.” He continued,
“We are now coupling that experience with our past and ongoing efforts to better understand and treat PTSD and AUD. We are confident that our studies will lead to benefits. Our returning veterans, in particular, who suffer from PTSD resulting from their military service, deserve our best efforts.”
Dr. Bogenshutz of the NYU School of Medicine added to the press release,
“Preclinical work and limited human experience suggest that CBD may have anti-addictive effects that may be useful in the treatment of alcohol use disorder and other substance use disorders.” He continued, “Our study is the first to investigate the effects of CBD in the treatment of alcohol use disorder, and will provide important new information on its mechanisms of action and clinical benefits.”